For Surgeons
Lumicell is working to change the landscape of cancer surgery with a hand-held imaging system that has the potential to help to identify cancer cells left behind on the tumor cavity walls and take action in real-time to improve patient outcomes.
For Patients
Lumicell is working to change the number one challenge in cancer surgery – the need to remove cancer cells during the first surgery while preserving healthy tissue.
News
Lumicell Appoints Brent Palmisano Chief Commercial Officer, Builds Commercial Team
Lumicell, Inc - a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced it is building a commercial team to prepare for market launch of the Lumicell Direct Visualization System (DVS), which includes its novel optical imaging agent LUMISIGHT, upon FDA approval. The company appointed industry veterans Brent Palmisano as chief commercial officer and Lauren Cohen as vice president of marketing and communications.
Clinical Data on Lumicell’s Direct Visualization System to Be Presented at International Conference on Surgical Cancer Care
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced that clinical data from a 234-patient, multi-center feasibility study of the Lumicell Direct Visualization System (DVS) will be presented at the Society of Surgical Oncology’s International Conference on Surgical Cancer Care (SSO2022). The system will also be featured in an industry-sponsored symposium at the conference, which is taking place March 9-12 in Dallas.